The EMA's CHMP recommends the permanent discontinuation of lacosamide [Vimpat] 15 mg/mL syrup. Media release 18 January 2013 Pages: 3 - 3
The EMA confirms that Revlimid's [lenalidomide's] benefit-risk balance remains positive, Media release 18 January 2013 Pages: 3 - 3
EMA advises contraindications for terpenic-based antitussives Media release 18 January 2013 Pages: 3 - 3